Art. -Nr.: HY-10158

Copy Link Print Information

Bosutinib

(Synonyms: SKI-606)

24 Cited Publications

Kundenbewertung

Based on 24 publication(s) in Google Scholar

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 380843-75-4
Formel: C₂₆H₂₉Cl₂N₅O₃
Molecular Weight:530.45

Speicherung:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Bosutinib Chemical Structure

CAS. Nr.: 380843-75-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (24)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively^[1].

IC₅₀ & Target

IC50: 1.2 nM (Src), 1 nM (Abl)^[1]

Alle Src Isoform-spezifische Produkte anzeigen :

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen :

Abl
Bcr-Abl

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	IC₅₀	>10 μM Compound: SKI-606	Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay	[PMID: 16970400]
BaF3	IC₅₀	>20 μM Compound: SKI-606	Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay	[PMID: 16970400]
BaF3	IC₅₀	0.15 μM Compound: SKI-606	Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay	[PMID: 16970400]
BaF3	IC₅₀	0.2 μM Compound: SKI-606	Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay	[PMID: 16970400]
BaF3	IC₅₀	0.2 μM Compound: SKI-606	Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay	[PMID: 16970400]
BaF3	IC₅₀	1 μM Compound: SKI-606	Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay	[PMID: 16970400]
BaF3	IC₅₀	3.2 μM Compound: Bosutinib	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay	[PMID: 26814890]
Fibroblast	IC₅₀	0.49 μM Compound: SKI-606	Inhibitory concentration against Abl transformed rat fibroblast cells Inhibitory concentration against Abl transformed rat fibroblast cells	[PMID: 16161995]
Fibroblast	IC₅₀	100 nM Compound: 1a	Inhibition of human cSrc-vSrc fusion protein expressed in rat fibroblast cells by ELISA Inhibition of human cSrc-vSrc fusion protein expressed in rat fibroblast cells by ELISA	[PMID: 17905586]
Fibroblast	IC₅₀	100 nM Compound: 1, SKI-606	Antiproliferative activity against Src-transformed rat2 fibroblast cells Antiproliferative activity against Src-transformed rat2 fibroblast cells	[PMID: 17181170]
HeLa	IC₅₀	3.85 μM Compound: Bosutinib	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HepG2	GI₅₀	1.15 μM Compound: bosutinib, SKI-606	Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 18485715]
HepG2	IC₅₀	3.91 μM Compound: bosutinib, SKI-606	Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 18485715]
HT-29	GI₅₀	1.17 μM Compound: bosutinib, SKI-606	Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B assay	[PMID: 18485715]
HT-29	IC₅₀	3.87 μM Compound: bosutinib, SKI-606	Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B assay	[PMID: 18485715]
HT-29	IC₅₀	5 μM Compound: 31a	Inhibition of HT-29 cell monolayer proliferation at 5 uM Inhibition of HT-29 cell monolayer proliferation at 5 uM	[PMID: 11689083]
K562	IC₅₀	0.0043 μM Compound: Bosutinib	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26814890]
K562	IC₅₀	20 nM Compound: 1 (SKI-606)	Inhibition of K562 leukemia cell proliferation Inhibition of K562 leukemia cell proliferation	[PMID: 15027848]
K562	IC₅₀	20 nM Compound: 1 (SKI-606)	Inhibition of K562 cell proliferation Inhibition of K562 cell proliferation	[PMID: 15916442]
MDA-MB-231	IC₅₀	1.8 μM Compound: 36	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 32688199]
MEG-01	IC₅₀	13 nM Compound: 3	Antiproliferative activity against human MEG-01 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo Luminescent assay Antiproliferative activity against human MEG-01 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo Luminescent assay	[PMID: 38116407]
MOLT-4	IC₅₀	>2000 nM Compound: 3	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo Luminescent assay Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo Luminescent assay	[PMID: 38116407]
Src-transformed	IC₅₀	100 nM Compound: 1 (SKI-606)	Inhibition of Src-transformed cell proliferation Inhibition of Src-transformed cell proliferation	[PMID: 15027848]
Src-transformed	IC₅₀	100 nM Compound: 2	Inhibition of Src-transformed cell proliferation Inhibition of Src-transformed cell proliferation	[PMID: 14552782]
SUP-B15	IC₅₀	210 nM Compound: 3	Antiproliferative activity against human SUP-B15 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo Luminescent assay Antiproliferative activity against human SUP-B15 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo Luminescent assay	[PMID: 38116407]
Vero C1008	CC₅₀	>1 μM Compound: 19	Cytotoxicity against African green monkey Vero E6 cells Cytotoxicity against African green monkey Vero E6 cells	[PMID: 33539089]

In Vitro

Bosutinib (SKI-606) is an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines, with IC₅₀ values in the low nanomolar range^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

The leukemic Bcr-Abl+ cell lines (KCL22, K562, KU812, and Lama84)
Concentration:

0.1 μmol/L
Incubation Time:

72 h
Result:

Inhibited several human CML derived cell lines with IC₅₀ values ranging from 1 to 20 nmol/L

In Vivo

Bosutinib (oral gavage; 75 mg/kg twice daily or 150 mg/kg once daily) has activity against human KU812 xenografts in nude mice. Bosutinib (150 mg/kg; once daily, 5 days weekly) has activity against syngeneic Bcr-Abl WT and mutant Ba/F3 xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KU812CM L xenograft model^[2]
Dosage:

75 mg/kg twice daily or 150 mg/kg once daily
Administration:

Bosutinib (oral gavage; 75 mg/kg twice daily or 150 mg/kg once daily)
Result:

Had the therapeutic activity and produced a dose- and schedule-dependent weight loss.

Animal Model:

Syngeneic Bcr-Abl WT and mutant Ba/F3 xenografts^[2]
Dosage:

150 mg/kg
Administration:

Bosutinib (150 mg/kg; once daily, 5 days weekly)
Result:

Decreased the rate of tumor growth and prolonged event-free survival of mice.

Chemical Information

CAS. Nr. 380843-75-4
Appearance Solid
Molecular Weight 530.45
Formel C₂₆H₂₉Cl₂N₅O₃
Color White to yellow
SMILES

CN1CCN(CC1)CCCOC2=C(C=C3C(NC4=CC(OC)=C(C=C4Cl)Cl)=C(C=NC3=C2)C#N)OC
Synonyms

SKI-606
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (24)

All Cell Imaging/StainingWBFlow CytometryCell Proliferation/Viability AssayHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]

2023 Apr 24;14(1):2342. PMID: 37095176
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Nanobiotechnology

Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects. [Abstract]

2023 Mar 21;21(1):102. PMID: 36945003
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Sci Adv

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. [Abstract]

2024 Dec 13;10(50):eadq4274. PMID: 39661665

Bosutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

Bright-field microscopy images of 3D sphere cultures of MIA PaCa-2R and mKRC.1 with vehicles, MRTX849, dasatinib, DGY-06-116, and Bosutinib (0.1 μM) as well as combinations, after 7 days of treatment.

Bosutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

The combined use of Bosutinib (0.1 μM), DGY-06-116, or Dasatinib with MRTX849 demonstrated a similar synergistic effect in mKRC.1 cells.

Bosutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

Representative images of H&E staining of the liver, lung, pancreas, and spleen from mice bearing mKRC.1 tumors, treated with either vehicle or the combination of MRTX849 and Bosutinib.
Biomaterials

FAK-p38 signaling serves as a potential target for reverting matrix stiffness-modulated liver sinusoidal endothelial cell defenestration. [Abstract]

2024 Mar:305:122462. PMID: 38171118
Int J Biol Macromol

Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. [Abstract]

2024 Dec 2:138305. PMID: 39631575
EPMA J

Glioma angiogenesis phosphoproteome landscape and biomarker sets identified with phenome-centered multiomics toward 3P medical approaches. [Abstract]

2025 Nov 3;16(4):831-856. PMID: 41312000
Drug Des Devel Ther

LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. [Abstract]

2021 Sep 15:15:3915-3925. PMID: 34552321
Biomacromolecules

Comparative Study of pH-Responsive and Aggregation Stability of Bosutinib-Loaded Nanogels Comprising Gelatin Methacryloyl, Carboxymethyl Dextran, and Hyaluronic Acid for Controlled Drug Delivery in Colorectal Cancer: An Extensive In Vitro Investigation. [Abstract]

2024 Dec 9;25(12):7926-7950. PMID: 39504130
Biomolecules

Investigating the Effect of Tyrosine Kinase Inhibitors on the Interaction between Human Serum Albumin by Atomic Force Microscopy. [Abstract]

2022 Jun 11;12(6):819. PMID: 35740944
J Pathol

Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities. [Abstract]

2023 Jun;260(2):203-221. PMID: 36825655
Front Pharmacol

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. [Abstract]

2021 Mar 8;12:644342. PMID: 33790797
ACS Omega

Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2. [Abstract]

2023 Jun 14;8(25):22603-22612. PMID: 37387790
Target Oncol

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features. [Abstract]

2020 Oct;15(5):659-671. PMID: 32780298
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
ACS Med Chem Lett

Atypical N-Alkyl to N-Noralkoxy Switch in a Dual cSRC/BCR-ABL1 Kinase Inhibitor Improves Drug Efflux and hERG Affinity. [Abstract]

2023 Dec 5;14(12):1869-1875. PMID: 38116407
Life Sci Alliance

Integrin β1/FAK/SRC signal pathway is involved in autism spectrum disorder in Tspan7 knockout rats. [Abstract]

2022 Dec 20;6(3):e202201616. PMID: 36625203

Bosutinib purchased from MedChemExpress. Usage Cited in: Life Sci Alliance. 2022 Dec 20;6(3):e202201616. [Abstract]

Primary neurons from embryo brains of of WT rats and Tspan7−/− rats at E17 were cultured for 6 d. The WT neurons were treated without or with 10 μM Bosutinib for 4 h. Then phosphorylated and total SRC, PSD95, SYN, GluR1, and GluR2 in the primary neurons were detected with Western blot.
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Biochem Biophys Res Commun

Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]

2020 Feb 19;522(4):862-868. PMID: 31806372
bioRxiv

2025 February 26.
Biomed Pharmacother

Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib. [Abstract]

2024 Jul 24:178:117114. PMID: 39053425
Saudi J Biol Sci

Protective effect of Bosutinib with caspase inhibitors on human K562 cells. [Abstract]

2022 Apr;29(4):2323-2328. PMID: 35531147

Bosutinib purchased from MedChemExpress. Usage Cited in: Saudi J Biol Sci. 2022 Apr;29(4):2323-2328. [Abstract]

K562 cells were incubated with Bosutinib (BOS) (250 nM) in the absence or addition of Boc-D-FMK (5 μM) for up to 48 h. Cell cycle phase distribution was assessed using flow cytometry, PI labeling of total DNA content, and the Guava Cell Cycle Assay software module. Left to right; colored areas indicate sub-G1, G0/G1, S and G2/M phases.
Technical University of Munich

24.01.2018.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 46 mg/mL (86.72 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8852 mL

9.4260 mL

18.8519 mL

5 mM

0.3770 mL

1.8852 mL

3.7704 mL

10 mM

0.1885 mL

0.9426 mL

1.8852 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92. [Content Brief]

[2]. Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66(23):11314-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8852 mL	9.4260 mL	18.8519 mL	47.1298 mL
	5 mM	0.3770 mL	1.8852 mL	3.7704 mL	9.4260 mL
	10 mM	0.1885 mL	0.9426 mL	1.8852 mL	4.7130 mL
	15 mM	0.1257 mL	0.6284 mL	1.2568 mL	3.1420 mL
	20 mM	0.0943 mL	0.4713 mL	0.9426 mL	2.3565 mL
	25 mM	0.0754 mL	0.3770 mL	0.7541 mL	1.8852 mL
	30 mM	0.0628 mL	0.3142 mL	0.6284 mL	1.5710 mL
	40 mM	0.0471 mL	0.2356 mL	0.4713 mL	1.1782 mL
	50 mM	0.0377 mL	0.1885 mL	0.3770 mL	0.9426 mL
	60 mM	0.0314 mL	0.1571 mL	0.3142 mL	0.7855 mL
	80 mM	0.0236 mL	0.1178 mL	0.2356 mL	0.5891 mL

Keywords

Bosutinib

24 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bosutinib

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Bosutinib

Alle Src Isoform-spezifische Produkte anzeigen

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (24)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bosutinib Related Classifications

HY-10158 Related Classifications